

## Immunic, Inc. to Participate in Investor and Scientific Conferences in March

**NEW YORK, March 8, 2022 – Immunic, Inc. (Nasdaq: IMUX)**, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March:

- **March 13-15: 34th Annual Roth Conference.** Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic, will participate in a fireside chat at the 34<sup>th</sup> Annual Roth Conference in Dana Point, CA on Tuesday, March 15, at 10:30 am PT. A live webcast of the presentation will be available on the “Events and Presentations” section of Immunic’s website at: [ir.imux.com/events-and-presentations](http://ir.imux.com/events-and-presentations). An archived replay will be available on the company’s website for a period of 90 days after the conference.
- **March 22-23: Clinical Trial Supply Europe 2022.** Members of Immunic’s chemistry, manufacturing and controls (CMC) team will attend this conference in Madrid, Spain.
- **March 25-29: 2022 American Academy of Dermatology (AAD) Annual Meeting.** Members of the company’s business development and IMU-935 clinical teams will attend this conference in Boston, MA.
- **March 29-31: Drug Information Association (DIA) Europe 2022.** Members of Immunic’s regulatory, pharmacovigilance and CMC teams will attend this conference taking place in Brussels, Belgium and virtually.
- **March 30 - April 2: 31st Annual Meeting of the Society for Virology.** Members of the company’s preclinical team will attend this conference taking place in Munich, Germany and virtually.

### About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR $\gamma$ /ROR $\gamma$ t, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: [www.imux.com](http://www.imux.com).

### Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy,



future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s participation in investor and scientific conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 24, 2022, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at [www.sec.gov](http://www.sec.gov) or [ir.imux.com/sec-filings](http://ir.imux.com/sec-filings). Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

## **Contact Information**

### **Immunic, Inc.**

Jessica Breu  
Head of Investor Relations and Communications  
+49 89 2080 477 09  
[jessica.breu@imux.com](mailto:jessica.breu@imux.com)

### **US IR Contact**

Rx Communications Group  
Paula Schwartz  
+1 917 322 2216  
[immunic@rxir.com](mailto:immunic@rxir.com)

### **US Media Contact**

KOGS Communication  
Edna Kaplan  
+1 781 639 1910  
[kaplan@kogspr.com](mailto:kaplan@kogspr.com)